Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform

METiS TechBio’s AiLNP platform uses machine learning models to develop lipid nanoparticles with potentially better tissue specificity that could enhance a drug’s therapeutic performance.